Dr. Misty Shields’ Mission to Change Small Cell Lung Cancer
June 15, 2026
When Misty Shields was 13 years old, her father was diagnosed with small cell lung cancer (SCLC). He was 48. Within 2 years, he was gone.
That loss changed everything for her. While other teenagers were figuring out who they wanted to be, Misty was looking online to find out how to become an oncologist. She had found her purpose, even if it came wrapped in grief.
Today, Misty Shields, MD, PhD, is one of the leading researchers and clinicians working to make SCLC a more treatable disease. She sat down with GO2’s Chief Patient Officer, Danielle Hicks, at a recent Lung Cancer Living Room® to share what’s changing in the world of SCLC and why she believes real hope is finally within reach.
Watch the full Lung Cancer Living Room conversation with Dr. Misty Shields on SCLC below.
A disease that went decades without progress
For most of the last 50 years, the story of SCLC treatment hasn’t changed much. Chemotherapy was the main tool, and it often worked for a little while, but not for long or well enough. Unlike non-small cell lung cancer (NSCLC), which saw a wave of new targeted therapies and immunotherapies reshape outcomes over the past decade, SCLC lagged behind.
That personal history is part of why Dr. Shields pushed into this field. “SCLC has been neglected for a long time,” she said. “That’s not acceptable.”
The treatments that are changing the picture
The first real turning point came in 2018 and 2019, when the Food and Drug Administration (FDA) approved the first immunotherapy drugs for SCLC. Drugs like Tecentriq (atezolizumab) and Imfinzi (durvalumab) work by releasing the brakes on the immune system, helping it recognize and attack cancer cells. They are used alongside or after chemotherapy, depending on the stage of disease, and they are helping some people with SCLC live longer.
Then, in 2025, a new treatment for SCLC was approved by the FDA. Dr. Shields explained that Imdelltra (tarlatamab) is a drug that works in a completely different way. Think of it as a connector. It acts like glue between the immune system’s T-cells and the cancer cells, pulling them together so the immune system can do its job. This approach, called a T-cell engager, is now the standard second-line treatment for extensive-stage (stage 4 (IV)) SCLC. It represents the first major shift in what doctors reach for when cancer stops responding to first-line therapy.
SCLC isn’t one disease anymore
For decades, doctors treated all SCLC the same way. That’s also starting to change. Researchers have discovered that SCLC has distinct subtypes, or different versions of the disease that may behave differently and respond differently to treatment.
This is the same shift that happened in NSCLC years ago, and it opened the door to targeted therapies that dramatically improved outcomes for many people. The hope is that identifying SCLC subtypes will do the same. The work is still in early stages, but the direction is clear: the future of SCLC treatment will likely be more personalized, not one-size-fits-all.
Finding SCLC earlier and understanding it better
SCLC is often caught late, partly because it can grow and spread quickly. Researchers are now looking at new tools that could change that. Liquid biopsies, or blood tests that detect cancer cells or fragments of cells in the bloodstream, may help doctors diagnose SCLC earlier or track how the cancer changes over time. Multi-cancer early detection tests are also being studied to flag cancers such as SCLC before symptoms appear.
For a fast-moving disease like SCLC, finding cancer earlier could dramatically change outcomes.
Clinical trials: progress requires participation
Every treatment Dr. Shields discussed exists because people with lung cancer agreed to be part of a clinical trial. It’s worth saying that plainly, because trials are still widely misunderstood.
A clinical trial is not a last resort. It often means people gain access to the newest treatments before they are widely available. For people with SCLC, that access can matter enormously, especially because the disease tends to progress quickly.
People with SCLC often face barriers to joining trials, such as strict eligibility requirements, how fast the disease progresses, and the need to act quickly. Researchers know this is a problem. Many are now designing studies with more flexible rules and faster enrollment to make sure more people can participate. More participants mean faster answers, and faster answers mean better treatments for everyone who comes after.
“The nihilism is no longer welcome.”
Dr. Shields closed the conversation with a message she clearly feels deeply: “Never give up hope. The breakthrough might be just right around the corner. This is the new era for small cell lung cancer, and the nihilism is no longer welcome.”
For the 15-year-old who lost her father to this disease, that shift is personal. For the people living with SCLC today, it may be life changing.
If you would like to learn more about SCLC, have questions, or need support, our SCLC program can help. Contact our free HelpLine at 1-800-298-2436 or email support@go2.org.